Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 14/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29875149 | 1.00 | MAT2A (0.52) | MAT2ABRD4CREBBPALDH1A1ADORA2A | |
| SCHEMBL19927671 | 0.90 | MAT2A (0.53) | MAT2AALDH1A1 | |
| SCHEMBL19936241 | 0.90 | MAT2A (0.56) | MAT2AALDH1A1 | |
| SCHEMBL19926739 | 0.89 | MAT2A (0.48) | MAT2AALDH1A1 | |
| SCHEMBL19972078 | 0.86 | MAT2A (0.52) | MAT2AALDH1A1 | |
| SCHEMBL19972068 | 0.85 | MAT2A (0.52) | MAT2AALDH1A1 | |
| SCHEMBL19926860 | 0.85 | MAT2A (0.51) | MAT2AALDH1A1 | |
| SCHEMBL19927037 | 0.84 | MAT2A (0.66) | MAT2AALDH1A1 | |
| SCHEMBL19926347 | 0.84 | MAT2A (0.44) | MAT2AALDH1A1 | |
| SCHEMBL19926494 | 0.84 | MAT2A (0.47) | MAT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49934-E1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2024-04-23 | — | — | US | disclosed |
| US-11325914-B1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-11325914-B1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2022-05-10 | — | — | US | disclosed |
| WO-2021158792-A1 | METHODS OF TREATING AUTOIMMUNE OR INFLAMMATORY DISEASES OR DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-10800782-B2 | Inhibitors of cellular metabolic processes | Agios Pharmaceutical, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800782-B2 | Inhibitors of cellular metabolic processes | Agios Pharmaceutical, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190233424-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2019-08-01 | — | — | US | disclosed |
| US-20190233424-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2019-08-01 | — | — | US | disclosed |
| EP-3507290-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | Agios Pharmaceuticals, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| US-10329298-B2 | Inhibitors of cellular metabolic processes | AGIOS PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-10329298-B2 | Inhibitors of cellular metabolic processes | AGIOS PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2018-03-22 | — | — | US | disclosed |
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2018-03-22 | — | — | US | disclosed |
| WO-2018045071-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | AGIOS PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329298-B2 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | MAT2A 2/4885BRD4 3321/4885CREBBP 529/4885 |
| US-20190233424-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | MNAT1, MAT2A, PCK2 | MAT2A 2/4885BRD4 3321/4885CREBBP 529/4885 |
| US-10800782-B2 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | MAT2A 2/4885BRD4 3321/4885CREBBP 529/4885 |
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | MNAT1, MAT2A, PCK2 | MAT2A 2/4885BRD4 3321/4885CREBBP 529/4885 |
| US-11325914-B1 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | MAT2A 2/4885BRD4 3321/4885CREBBP 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.